ArticleBMJ case reports2022
Balloon pulmonary angioplasty in inoperable chronic thromboembolic pulmonary hypertension.
Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Balloon pulmonary angioplasty (BPA) is an emerging treatment for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or residual/recurrent pulmonary hypertension after pulmonary thromboendarterectomy. We report two patients with inoperable and severe CTEPH who were submitted to the BPA programme after optimised treatment with long-term oxygen therapy (LTOT) and pulmonary vasodilator drugs, including prostacyclin analogues. They experienced a significant improvement in exercise capacity, oxygenation, right ventricular function and pulmonary haemodynamics. This improvement allowed withdrawal from LTOT and prostacyclin analogues therapies and, consequently, improved patients' quality of life and reduced future health-related costs. The reported clinical cases intend to highlight the effectiveness of BPA in patients with inoperable CTEPH for whom the only available therapy was, until recently, the pulmonary vasodilator drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.